Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation [PDF]
Majalah Kedokteran Bandung, 2019 Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL.
Martalena Ramli +4 more
doaj +3 more sources
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. [PDF]
PLoS ONE, 2017 Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker
Yvonne W S Jauw +7 more
doaj +2 more sources
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study [PDF]
Journal of Clinical Oncology, 2021 PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE.
C. Buske +19 more
semanticscholar +2 more sources
Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [PDF]
Journal of Hematology & Oncology, 2012 Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier +14 more
doaj +2 more sources
Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness [PDF]
ClinicoEconomics and Outcomes Research, 2010 Firas Badin, John HayslipUniversity of Kentucky, Markey Cancer Center, Lexington, KY, USAAbstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent
Firas Badin, John Hayslip
doaj +2 more sources
Case series of low dose rituximab for membranous nephropathy; a single centre experience [PDF]
Journal of Nephropathology, 2023 Introduction: Rituximab is the recent treatment of choice for primary membranous nephropathy However, dose of rituximab mentioned in literature is high and not economical in middle income countries.
Gerry George Mathew +2 more
doaj +1 more source
Probing the sensitivity of autoantibody production to B cell depletion by Rituximab [PDF]
, 2010 Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are
Ferraro, Alastair James
core +7 more sources
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
Frontiers in Immunology, 2023 BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period.
Chutima Seree-aphinan +9 more
doaj +1 more source
RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA
Hematology, Transfusion and Cell Therapy, 2022 Objective: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological.
Taha Ulutan Kars +3 more
doaj +1 more source
Nature Medicine, 2022 Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue.
Felice Rivellese +20 more
semanticscholar +1 more source